HK1171457A1 - Lipidated tumor-associated antigens and immunotherapeutic compositions - Google Patents

Lipidated tumor-associated antigens and immunotherapeutic compositions

Info

Publication number
HK1171457A1
HK1171457A1 HK12112180.1A HK12112180A HK1171457A1 HK 1171457 A1 HK1171457 A1 HK 1171457A1 HK 12112180 A HK12112180 A HK 12112180A HK 1171457 A1 HK1171457 A1 HK 1171457A1
Authority
HK
Hong Kong
Prior art keywords
lipidated
tumor
associated antigens
immunotherapeutic compositions
immunotherapeutic
Prior art date
Application number
HK12112180.1A
Other languages
English (en)
Chinese (zh)
Inventor
冷治湘
陳信偉
劉士任
庄再成
Original Assignee
財團法人衛生研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 財團法人衛生研究院 filed Critical 財團法人衛生研究院
Publication of HK1171457A1 publication Critical patent/HK1171457A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/915—Fusion polypeptide containing a motif for post-translational modification containing a motif for acylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK12112180.1A 2009-06-22 2012-11-27 Lipidated tumor-associated antigens and immunotherapeutic compositions HK1171457A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21930109P 2009-06-22 2009-06-22
PCT/CA2010/000960 WO2010148496A1 (en) 2009-06-22 2010-06-22 Lipidated tumor- associated antigens and immunotherapeutic compositions

Publications (1)

Publication Number Publication Date
HK1171457A1 true HK1171457A1 (en) 2013-03-28

Family

ID=43354578

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12112180.1A HK1171457A1 (en) 2009-06-22 2012-11-27 Lipidated tumor-associated antigens and immunotherapeutic compositions

Country Status (6)

Country Link
US (1) US8658176B2 (xx)
EP (1) EP2445927B1 (xx)
CN (1) CN102482327B (xx)
HK (1) HK1171457A1 (xx)
TW (1) TWI409275B (xx)
WO (1) WO2010148496A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426163B2 (en) * 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US8287880B2 (en) * 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
EP2445927B1 (en) 2009-06-22 2014-04-23 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
IN2012DN00791A (xx) 2009-06-29 2015-06-26 Genocea Biosciences Inc
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
MX344120B (es) 2011-01-20 2016-12-06 Genocea Biosciences Inc Vacunas y composiciones contra streptococcus pneumoniae.
WO2013134656A1 (en) * 2012-03-09 2013-09-12 Genocea Biosciences, Inc. Induction of th17 immune response
JP6947727B2 (ja) * 2015-12-10 2021-10-13 ナショナル リサーチ カウンシル オブ カナダ 脂質化肺炎球菌抗原組成物、調製方法及び使用
TWI670280B (zh) * 2016-02-23 2019-09-01 財團法人國家衛生研究院 人類乳突病毒之脂質抗原及用於人類乳突病毒相關疾病之免疫治療組合物
TWI628189B (zh) * 2016-02-23 2018-07-01 財團法人國家衛生研究院 脂質化存活素（ｓｕｒｖｉｖｉｎ）及其用以預防及治療癌症之用途
GB202020135D0 (en) * 2020-12-18 2021-02-03 Ucl Business Ltd Immunogenic peptide

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745069A (en) 1982-05-25 1988-05-17 Eli Lilly And Company Cloning vectors for expression of exogenous protein
WO1992005248A1 (en) 1990-09-26 1992-04-02 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
EP0878545A3 (en) 1991-08-15 1998-12-16 SMITHKLINE BEECHAM BIOLOGICALS s.a. OSP a protein of borrelia burgdorferi subgroups, encoding genes and vaccines
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
ZA964896B (en) 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
US6251405B1 (en) 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
GB9614700D0 (en) 1996-07-12 1996-09-04 Medical Res Council Over-expression of proteins in E.Coli
CA2183146A1 (en) 1996-08-12 1998-02-13 Thomas C. Bower Method and apparatus for management wastewater effluent from various wastewater effluent sources
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US6395904B1 (en) 1997-08-26 2002-05-28 Yale University Binuclear non-heme iron catalysts
US6013258A (en) 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
EP2261347A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
US7452715B1 (en) 1999-06-25 2008-11-18 Wyeth Holdings Corporation Production of the lipidated form of the peptidoglycan associated lipoproteins of gram-negative bacteria
GB9924506D0 (en) 1999-10-15 1999-12-15 Medical Res Council Expression system
ATE383871T1 (de) 2000-02-18 2008-02-15 Vlaams Interuniv Inst Biotech Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene
EP1490106B1 (de) 2002-04-04 2008-05-28 Helmholtz-Zentrum für Infektionsforschung GmbH Verwendung eines lipopeptids oder lipoproteins als adjuvans bei therapeutischer oder prophylaktischer vakzinierung
FR2839072A1 (fr) 2002-04-24 2003-10-31 Neovacs Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
DK1543039T3 (da) 2002-08-12 2011-10-31 Queensland Inst Med Res Nye immunogene lipopeptider omfattende T-hjælper- og B-celle-epitoper
GB0228715D0 (en) 2002-12-09 2003-01-15 Glaxosmithkline Biolog Sa Vaccine
US7357932B2 (en) 2004-06-16 2008-04-15 Center Of Disease Control Department Of Health Surface protein of Neisseria bacteria
EP1612218B1 (en) 2004-06-29 2008-05-14 Center for Disease Control Department of Health Taiwan Surface protein of Neisseria bacteria
KR20070116650A (ko) 2005-03-23 2007-12-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 조성물
CN1793335A (zh) 2005-11-16 2006-06-28 上海美迪西生物医药有限公司 硒代蛋氨酸标记的蛋白高产表达培养基配方及其应用
CN101421306B (zh) 2006-04-19 2013-09-18 浦项工科大学校产学协力团 用于治疗和预防子宫颈癌的包含hpv多肽和免疫增强肽的组合物
WO2008046251A1 (fr) * 2006-10-19 2008-04-24 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées
JP2008113608A (ja) 2006-11-06 2008-05-22 Yokohama City Univ 培地及びそれを用いた、目的ポリペプチドを１５ｎで標識する方法
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US7981431B2 (en) 2007-06-08 2011-07-19 National Health Research Institutes Consensus dengue virus envelope protein domain III polypeptides (cED III) and their methods of use
EP2058002A1 (en) 2007-10-31 2009-05-13 Bestewil Holding B.V. Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine
US7833776B2 (en) * 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
US8426163B2 (en) 2007-12-07 2013-04-23 National Health Research Institutes Production of lipidated proteins in E. coli
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
EP2445927B1 (en) 2009-06-22 2014-04-23 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
TWI503411B (zh) 2010-08-11 2015-10-11 Nat Health Research Institutes Ｂ群腦膜炎球菌次單位疫苗之製造及純化

Also Published As

Publication number Publication date
EP2445927A4 (en) 2012-12-19
TW201103946A (en) 2011-02-01
EP2445927B1 (en) 2014-04-23
TWI409275B (zh) 2013-09-21
US20100322953A1 (en) 2010-12-23
WO2010148496A8 (en) 2011-03-03
WO2010148496A1 (en) 2010-12-29
CN102482327A (zh) 2012-05-30
CN102482327B (zh) 2014-10-29
US8658176B2 (en) 2014-02-25
EP2445927A1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
HK1171457A1 (en) Lipidated tumor-associated antigens and immunotherapeutic compositions
HK1223382A1 (zh) 免疫療法的新型免疫抗原表位
GB0714963D0 (en) Compositions comprising antigens
IL212834A0 (en) Compositions comprising cd37 immunotherapeutic combinations and uses thereof
IL230863B (en) Immunotherapeutic compositions of 1muc-shemer and their uses
HK1168117A1 (zh) 抗- 抗體及其用途
EP2181121A4 (en) CHIMÄRE ANTIGENE
PT3091034T (pt) Anticorpos anti-cd40 e seus usos
ZA201106480B (en) Humanized anti-cd19 antibody formulations
EP2429585A4 (en) VACCINE IMMUNOTHERAPY
GB0922434D0 (en) antibodies and fragments thereof
IL217166A0 (en) Vaccines and compositions against stretococcus pneumoniae
EP2542589A4 (en) ANTIBODIES AND COMPOSITIONS ANTI-HER2
IL208445A0 (en) Compositions and methods for immunotherapy
IL219470A (en) Antibacterial antibody, preparations containing it and its uses
EP2515940A4 (en) IMMUNOGENIC COMPOSITIONS AND CORRESPONDING METHODS
EP2400984A4 (en) HER2 ANTIBODY COMPOSITIONS
EP2185577A4 (en) CHLAMYDIA ANTIGENS
EP2413959A4 (en) CHLAMYDIA-ANTIGENE COMPREHENSIVE COMPOSITIONS
EP2569006A4 (en) DOMAIN N OF THE CARCINO-EMBRYONIC ANTIGEN AND ITS COMPOSITIONS, METHODS AND USES
IL208188A0 (en) Compositions comprising antibodies or antibody fragments
GB0908885D0 (en) Mycobacterial antigens
GB0723900D0 (en) Lyophillised antigen composition
GB0723044D0 (en) Lyophillised antigen composition
EP2227250A4 (en) ANTIGENS OF CHLAMYDIA